Početna › Mijelofibroza › Maryland
Kliničke studije za Mijelofibroza u državi Maryland
9 studija za Mijelofibroza traži sudionike na lokacijama u državi Maryland.
Gradovi u državi Maryland
Službeni tekst studije (engleski)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- University of Maryland, Baltimore
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT04176198A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- American Oncology Partners PA Center for Cancer and Blood Disorders, Bethesda
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT07357727Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
U tijeku regrutacijaRana faza 1
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT06398457A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- Johns Hopkins University, Baltimore
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 6. kol 2026. · NCT07008118Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- John Hopkins Hospital, Baltimore
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. srp 2026. · NCT07441694A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Johns Hopkins Hospital, Baltimore
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 17. tra 2026. · NCT06034002A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Maryland Oncology Hematology - Independent of SCRI/ US Oncology, Columbia
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 12. velj 2026. · NCT05980806SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Bethesda
- Massive Bio SYNERGY-AI site, Silver Spring
- i još 1
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 28. lis 2025. · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
- The Center for Cancer and Blood Disorders, Bethesda
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2025. · NCT06479135Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.